[Benzodiazepines and their mechanism of action].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Y Fujii.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The effects of oxybutynin, an anticholinergic and antispasmodic agent, on the cardiovascular system were studied in comparison with those of atropine in anesthetized dogs. Oxybutynin (0.1-10 mg/kg, i.v.) caused a transient hypotension, tachycardia, increases in femoral, stomach, mesenteric and common carotid arterial blood flows and a decrease in renal arterial blood flow. Atropine (0.1-10 mg/kg, i.v.) caused a stronger and more prolonged hypotension with bradycardia, accompanied by weaker blood flow changes than those by oxybutynin. In open-chest dogs, oxybutynin caused increases in cardiac output and coronary sinus outflow and decreases in heart rate and left ventricular pressure. The agent augmented dLVP/dt/P at doses up to 3 mg/kg, i.v., but reduced it at 10 mg/kg, i.v. Atropine caused stronger cardiosuppressive responses than those of oxybutynin. Coronary sinus outflow was decreased by atropine, unlike in the case of oxybutynin. The pressor responses of norepinephrine, epinephrine and tyramine were potentiated by pretreatment with oxybutynin (15 mg/kg, i.v.). However, pressor or depressor responses induced by histamine, isoproterenol, serotonin and DMPP were unaffected by oxybutynin. Intraarterial injections of oxybutynin, atropine and papaverine caused femoral and renal arterial vasodilations dose-dependently, in the following order of potency: papaverine greater than oxybutynin greater than atropine. In the isolated blood-perfused canine papillary muscle preparation, oxybutynin and atropine caused a negative inotropic action, whereas papaverine caused a positive inotropic action. From the above results, it is suggested that oxybutynin has milder cardiosuppressive and hypotensive effects than atropine in terms of potency and duration of action, and in addition, oxybutynin has a vasodilating action probably ascribable to its anticholinergic and antispasmodic actions.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The uptake and release of [3H]norepinephrine [( 3H]NE) were investigated using isolated rat globus pallidus slices to determine the possible neurotransmitter role of this catecholamine. The uptake into these slices was linear for the first 10 min. Kinetic analysis indicated two components of NE accumulation, one representing a high (Km1 2.9 X 10(-7) M and Vmax1 1.4 pmol/mg/10 min) and other a low (Km2 1.6 X 10(-6) M and Vmax2 5 pmol/mg/10 min) affinity uptake system. Desmethylimipramine at a concentration of 10(-5) M reduced the high affinity uptake of [3H]NE by 25% of the control values. Electrical stimulation of the slices increased the efflux of [3H]NE and its metabolites from tissues preloaded with [3H]NE, in a current- and frequency-dependent fashion. The release of [3H]NE and its metabolites induced by electrical stimulation (1 mA, 20 Hz, 1 ms for 2 min) was inhibited by tetrodotoxin (10(-6) M), and by a calcium-free medium containing EGTA (10(-4) M) or medium with a high magnesium-concentration (2 X 10(-2) M). These findings provide strong evidence for the neurotransmitter role of NE, in these tissues.
Treatment of rat liver-type pyruvate kinase with rabbit liver cathepsin B at pH 7.0 caused loss of activity in the standard assay with 0.6 mM of phosphoenolpyruvate. The modified enzyme exhibited about 10% of the original activity when assayed with 2.0 mM of the substrate. No detectable change in the subunit molecular weight of the enzyme occurred during inactivation. On addition of 4 microM fructose 1,6-bisphosphate the activity of the treated enzyme was restored to that of the original enzyme. Limited proteolysis of the enzyme by cathepsin B appears to enhance the requirement for the positive effector, fructose 1,6-bisphosphate.
The present study includes a histopathological and immunohistochemical study of 4 cases of diffuse hyperplasia of gastric argyrophil cells. The mode of proliferation of these cells and the production of hormone by these cells have been documented. The distribution of microacinar nests composed of argyrophil cells was thought to be related to chronic gastritis in which there are atrophy of mucosa and intestinal metaplasia. In the case in which these nests were found only in the corpus ventriculi, there was intestinal metaplasia throughout the stomach. On the other hand, in the case in which these nests appeared only in the pyloric area, atrophy of the mucosa with mild intestinal metaplasia was observed only in the pyloric area. The microacinar nests composed of argyrophil cells were distributed in the deep mucosa at the basal portion of the glands in the area with intestinal metaplasia. Serial sections revealed a sprout composed of argyrophil cells budding from the gland with intestinal metaplastic changes. The sprout buds out from the growth zone of glands with intestinal metaplasia and then becomes isolated and gives rise to reactive hyperplasia. The peptide hormone contained in these cells differs according to the mucosal environments. Cells containing gastrin were observed in the pyloric area, but not in the corpus ventriculi where there was marked intestinal metaplasia. The cells in this area were assumed to contain other hormones.
Pressor activity was demonstrated by the intravenous injection of purified epsilon toxin of Clostridium perfringens type D but not by that of epsilon prototoxin. The activity was completely abolished by C. perfringens type B or D antiserum, but not by type A, C, or E antiserum. The rise in blood pressure caused by the toxin was accompanied by a decrease in the blood flow in skin without any change of heart rate and electrocardiogram readings. These results indicate that epsilon toxin possesses pressor activity as well as lethal and dermonecrotic activities.
Plasminogen, a precursor of proteolytic enzyme plasmin which lyses thrombi in vivo, is postulated to be adsorbed onto fibrin and is converted into a modified form by plasmin. The properties of the modified form examined in vitro support this hypothesis. Nevertheless, it has been postulated that no conversion of native plasminogen into the modified form occurs in plasma, since alpha 2-plasmin inhibitor rapidly inactivates plasmin formed. However, we suggested production of the modified form in the "post-exercise" plasma. The present study was undertaken to examine production of the modified form in a simpler system, urokinase-activated plasma. The amount of the modified form in the plasma was estimated using the previous method with modification, epsilon-aminocaproic acid-containing polyacrylamide gel disc electrophoresis. The amount in the post-exercise plasma was also re-estimated by the present method. The amount of the modified form increased with the increase in urokinase concentration added to plasma. The presence of the modified form in the post-exercise plasma was also confirmed. The modified form could be produced in the plasma where an excess amount of alpha 2-plasmin inhibitor was expected to exist. The present results indicate that conversion of native plasminogen into the modified form may occur in vivo, supporting the hypothesis mentioned above.
Differences between the pharmacological effects of bromazepam given by oral and rectal administration were investigated in mice and rats. 1) Bromazepam dose-dependently prolonged the sleeping time induced by thiopental-Na, ethanol and ether by both administration routes. 2) The analgesic action of bromazepam was recognized by the hot-plate method and the algolytic test. In the hot-plate test, analgesic actions of morphine and pentazocine were potentiated by bromazepam in a dose of 0.5 mg/kg by both routes. 3) The muscle relaxant effect of bromazepam administered rectally was more potent than that administered orally in the inclined screen test and the rotarod test. This effect of bromazepam by rectal administration was approximately 2 times as potent as that by oral administration. 4) Bromazepam inhibited the convulsion induced by maximum electric shock, pentylenetetrazol and picrotoxin. In pentylenetetrazol-induced convulsion, the inhibitory effect of bromazepam administered rectally was 2 times as potent as that administered orally. In the other convulsion test, no significant differences between oral and rectal administration could be recognized. 5) Hyperemotionality and muricide (mouse-killing behaviour) of rats with bilateral olfactory bulb ablations (OB rat) were reduced by oral and rectal administrations of bromazepam in a dose-dependent manner. The effects by rectal administration were more potent than that by oral administration. Bromazepam was approximately 20 times as potent as diazepam administered by the same route. Fighting behaviour in mice subjected to footshock was suppressed by rectal administration of bromazepam, and this effect was as same as that by oral administration. 6) The rate of lever pressing response in the lateral hypothalamic self-stimulation test in the Skinner box was markedly increased by rectal administration of 0.2 mg/kg bromazepam. 7) Methamphetamine-induced hyperactivity of mice was significantly suppressed only by bromazepam administered rectally in a dose of 5 mg/kg. 8) The falling effect of bromazepam on body temperature in normal rats was the same in both administration routes and was dose-dependent. From these data, significant differences of the pharmacological effects between oral and rectal administration of bromazepam were recognized in the duration of action and, in part, potencies; and therefore, rectal administration of bromazepam may be a useful dosage form for clinical use.
Explore the source record for details and available documents.